Akebia Therapeutics Inc (AKBA)
1.83
+0.01
(+0.55%)
USD |
NASDAQ |
Nov 22, 09:58
Akebia Therapeutics Total Liabilities (Quarterly): 257.54M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 257.54M |
| June 30, 2024 | 253.95M |
| March 31, 2024 | 252.74M |
| December 31, 2023 | 272.29M |
| September 30, 2023 | 274.42M |
| June 30, 2023 | 280.52M |
| March 31, 2023 | 291.21M |
| December 31, 2022 | 350.82M |
| September 30, 2022 | 422.04M |
| June 30, 2022 | 459.50M |
| March 31, 2022 | 509.24M |
| December 31, 2021 | 455.34M |
| September 30, 2021 | 465.12M |
| June 30, 2021 | 437.23M |
| March 31, 2021 | 414.81M |
| December 31, 2020 | 396.52M |
| September 30, 2020 | 358.18M |
| June 30, 2020 | 374.91M |
| March 31, 2020 | 391.36M |
| December 31, 2019 | 376.44M |
| September 30, 2019 | 327.66M |
| June 30, 2019 | 304.17M |
| Date | Value |
|---|---|
| March 31, 2019 | 324.41M |
| December 31, 2018 | 360.61M |
| September 30, 2018 | 261.28M |
| June 30, 2018 | 247.86M |
| March 31, 2018 | 245.62M |
| December 31, 2017 | 241.67M |
| September 30, 2017 | 238.71M |
| June 30, 2017 | 279.82M |
| March 31, 2017 | 228.64M |
| December 31, 2016 | 232.10M |
| September 30, 2016 | 68.41M |
| June 30, 2016 | 62.35M |
| March 31, 2016 | 53.68M |
| December 31, 2015 | 11.94M |
| September 30, 2015 | 14.18M |
| June 30, 2015 | 5.913M |
| March 31, 2015 | 8.85M |
| December 31, 2014 | 6.917M |
| September 30, 2014 | 6.556M |
| June 30, 2014 | 4.806M |
| March 31, 2014 | 6.161M |
| December 31, 2013 | 3.91M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
252.74M
Minimum
Mar 2024
509.24M
Maximum
Mar 2022
364.71M
Average
375.68M
Median
Total Liabilities (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 145.42M |
| Eli Lilly and Co | 61.29B |
| Bioventus Inc | 582.66M |
| NovaBay Pharmaceuticals Inc | 2.805M |
| Palatin Technologies Inc | 11.10M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 207.14M |
| Shareholders Equity (Quarterly) | -50.40M |
| Debt to Equity Ratio | -0.761 |
| Current Ratio | 1.524 |
| Net Debt Paydown Yield | 0.30% |